Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Change in Accured Expenses (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Change in Accured Expenses for 15 consecutive years, with -$188000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses fell 8.05% year-over-year to -$188000.0, compared with a TTM value of -$290000.0 through Sep 2025, up 89.27%, and an annual FY2024 reading of -$1.2 million, up 70.82% over the prior year.
  • Change in Accured Expenses was -$188000.0 for Q3 2025 at Alaunos Therapeutics, down from $35000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.9 million in Q3 2022 and bottomed at -$7.3 million in Q4 2021.
  • Average Change in Accured Expenses over 5 years is -$864789.5, with a median of -$192000.0 recorded in 2024.
  • Peak annual rise in Change in Accured Expenses hit 209.65% in 2021, while the deepest fall reached 608.52% in 2021.
  • Year by year, Change in Accured Expenses stood at -$7.3 million in 2021, then soared by 70.13% to -$2.2 million in 2022, then grew by 21.07% to -$1.7 million in 2023, then surged by 88.91% to -$192000.0 in 2024, then rose by 2.08% to -$188000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for TCRT at -$188000.0 in Q3 2025, $35000.0 in Q2 2025, and $55000.0 in Q1 2025.